Five minutes with…Takanori Abe, Abe & Partners

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Five minutes with…Takanori Abe, Abe & Partners

Takanori.jpg

Each week Managing IP speaks to a different IP practitioner about their life and career

Welcome to the latest instalment of Managing IP’s ‘Five minutes with’ series, where we learn more about IP practitioners on a personal as well as a professional level. This time we have Takanori Abe, managing partner at Abe & Partners in Osaka

Someone asks you at a party what you do for a living. What do you say?

I help protect “what is important but invisible”.

Talk us through a typical working day.

Morning: coffee accompanied by Mozart’s 'Requiem' by Herbert von Karajan.

Afternoon: tea with Bach’s 'Goldberg Variations' by Glenn Gould.

Night: red wine with Chopin's 'Piano Concerto No.1' by Nobuyuki Tsujii.

All the way through, I am thinking about how to win my cases. In my dreams, I talk with the judge.

What are you working on at the moment?

I am representing large global pharmaceutical companies across various pharma patent cases. This includes infringement cases between two originating companies, an originator and a biosimilar, and originators and generics. I am also managing invalidation and opposition proceedings at the JPO.

Meanwhile, I am also advising multinational and domestic clients on fair, reasonable, and non-discriminatory matters for standard-essential patents.

Does one big piece of work usually take priority or are you juggling multiple things?

I am required to multi-task like an astronaut.

What is the most exciting aspect of your role and what is the most stressful?

Seeing a client’s smiling face when we have won a case and shaking hands with them is the most exciting. Seeing their sad face when we have lost is the most stressful.

Tell us the key characteristics that make a successful IP lawyer/practitioner.

Eagerness to draw a new map.

What is the most common misconception about IP?

Criticism from bioethics that IP benefits only the wealthy.

What or who inspires you?

Susumu Tonegawa, the 1987 Nobel Prize winner for physiology or medicine. He clarified the genetic mechanism of the adaptive immune system, which had been the central question of immunology for more than 100 years.

If you weren't in IP, what would you be doing?

I’d like to be a molecular biologist.

Any advice you would give your younger self?

None.

more from across site and SHARED ros bottom lb

More from across our site

Charles Harding plans to build a new team around life sciences oppositions and contentious work, drawing on his three decades developing a practice from scratch at D Young & Co
The firm reveals how its litigation strategies informed the arguments that took Masimo’s judgment past $818 million
The firm was rebuilding its IP practice through a string of patent hires and a Texas expansion, but its dissolution has put the newly built talent back into the market
AI can exploit longstanding gaps in copyright protection at remarkable speed, but EU law still provides tools to fight back, says Simon Hembt at Bird & Bird
The firm has tapped a local patent trio to establish a foothold in the market and broaden its national presence
New Asia-Pacific IP head Jonathan Chu is eyeing opportunities arising from Chinese technology licensing, overseas enforcement and increasingly IP-heavy cross-border deals
Europe’s largest intellectual property convention and trade fair is back: IP Service World 2026 takes place in Munich from November 23–25 – the 16th edition, with 1,400-plus attendees from 55-plus nations, 100-plus speakers, and 100-plus exhibitors. Three days. Two focused areas. One IP marketplace.
Mehmet Gün and Uğur Aktekin discuss four decades of change in Türkiye’s legal market, the firm’s commitment to independence and the challenge of building an institution that can outlast its founders
Boehringer Ingelheim has instructed a team from Kirkland, while Teva is being represented by Pinsent Masons
The Delhi High Court’s latest directions offer an opportunity to move beyond remedies against bad-faith registrations and address how suspicious applications are identified in the first place, says Fatima Baig at Lexlinc
Gift this article